ACRV Insider Trading

Insider Ownership Percentage: 8.50%
Insider Buying (Last 12 Months): $20,000,500.00
Insider Selling (Last 12 Months): $0.00

Acrivon Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Acrivon Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Acrivon Therapeutics Share Price & Price History

Current Price: $7.56
Price Change: Price Decrease of -0.13 (-1.69%)
As of 07/18/2024 01:00 AM ET

This chart shows the closing price history over time for ACRV up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Acrivon Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/11/2024Perceptive Advisors LlcMajor ShareholderBuy2,353,000$8.50$20,000,500.005,360,858View SEC Filing Icon  
6/26/2023Ltd ChioneMajor ShareholderSell16$12.93$206.883,848,632View SEC Filing Icon  
6/14/2023Ltd ChioneMajor ShareholderSell893$12.13$10,832.093,850,704View SEC Filing Icon  
6/12/2023Ltd ChioneMajor ShareholderSell2,000$12.34$24,680.003,854,597View SEC Filing Icon  
11/17/2022Ltd ChioneMajor ShareholderBuy400,000$12.50$5,000,000.003,856,597View SEC Filing Icon  
11/17/2022Ra Capital Management, L.P.DirectorBuy3,389,500$12.50$42,368,750.004,384,206View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Acrivon Therapeutics (NASDAQ:ACRV)

71.62% of Acrivon Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ACRV by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Acrivon Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/15/2024Baker BROS. Advisors LP52,885$0.38M0.0%N/A0.234%Search for SEC Filing on Google Icon
5/14/2024American International Group Inc.6,016$43K0.0%+39.2%0.027%Search for SEC Filing on Google Icon
5/10/2024Vanguard Group Inc.507,185$3.63M0.0%+6.6%2.241%Search for SEC Filing on Google Icon
1/5/2024Exchange Traded Concepts LLC13,289$65K0.0%+34.0%0.060%Search for SEC Filing on Google Icon
11/13/2023Federated Hermes Inc.226,375$2.16M0.0%-25.6%1.020%Search for SEC Filing on Google Icon
9/21/2023Barclays PLC14,263$0.18M0.0%-16.0%0.065%Search for SEC Filing on Google Icon
8/10/2023AAF Wealth Management LLC10,678$0.14M0.1%N/A0.049%Search for SEC Filing on Google Icon
7/20/2023Exchange Traded Concepts LLC11,709$0.15M0.0%N/A0.053%Search for SEC Filing on Google Icon
5/8/2023Federated Hermes Inc.613,625$7.79M0.0%-25.5%2.798%Search for SEC Filing on Google Icon
2/16/2023HealthCor Management L.P.284,201$3.27M3.0%N/A1.360%Search for SEC Filing on Google Icon
2/14/2023RA Capital Management L.P.4,810,508$55.42M1.1%N/A23.028%Search for SEC Filing on Google Icon
2/13/2023Sands Capital Ventures LLC1,652,605$19.04M5.2%N/A7.913%Search for SEC Filing on Google Icon
2/10/2023NEA Management Company LLC481,677$4.44M0.2%N/A2.306%Search for SEC Filing on Google Icon
2/1/2023Bank of Montreal Can42,444$0.55M0.0%N/A0.203%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Acrivon Therapeutics logo
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.
Read More on Acrivon Therapeutics

Today's Range

Now: $7.56
Low: $7.40
High: $7.67

50 Day Range

MA: $7.35
Low: $5.76
High: $8.89

52 Week Range

Now: $7.56
Low: $3.19
High: $13.50

Volume

86,471 shs

Average Volume

408,641 shs

Market Capitalization

$233.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86

Who are the company insiders with the largest holdings of Acrivon Therapeutics?

Acrivon Therapeutics' top insider shareholders include:
  1. Perceptive Advisors Llc (Major Shareholder)
  2. Ra Capital Management, LP (Director)
  3. Ltd Chione (Major Shareholder)
Learn More about top insider investors at Acrivon Therapeutics.